{"id":1283,"date":"2021-01-25T22:27:20","date_gmt":"2021-01-25T22:27:20","guid":{"rendered":"https:\/\/www.flowox.com\/?p=1283"},"modified":"2021-06-14T13:39:24","modified_gmt":"2021-06-14T13:39:24","slug":"study-confirms","status":"publish","type":"post","link":"https:\/\/flowox.com\/de\/study-confirms\/","title":{"rendered":"Studie best\u00e4tigt FlowOx\u2122 – Kosteneffektivit\u00e4t und verbesserte Lebensqualit\u00e4t"},"content":{"rendered":"\n

Studie best\u00e4tigt FlowOx\u2122 – Kosteneffektivit\u00e4t und verbesserte Lebensqualit\u00e4tx\u2122<\/h1>\n\n\n\n

Eine neue gesundheits\u00f6konomische Studie der Bangor Universit\u00e4t, Wales, Gro\u00dfbritannien, best\u00e4tigt, dass die FlowOx\u2122-Therapie in Kombination mit der Nominalversorgung die gesundheitsbezogene Lebensqualit\u00e4t der Patienten im Vergleich zur Standardversorgung verbessert und auch f\u00fcr die Kostentr\u00e4ger (in diesem Fall NHS (National Health Service – das staatliche Gesundheitssystem in Gro\u00dfbritannien)) kostensparend ist. Die Ergebnisse deuten darauf hin, dass die FlowOx\u2122-Therapie eine wirtschaftlich sinnvolle Behandlung ist.<\/strong><\/p>\n\n\n\n

<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Horizon 2020 Fast Track<\/h3>\n\n\n\n

Diese Publikation enth\u00e4lt Ergebnisse einer von der Europ\u00e4ischen Kommission im Rahmen des F\u00f6rderprogramms: \u201eHorizon 2020 Fast Track to Innovation\u201c finanzierten, unabh\u00e4ngigen Forschung, die am 14. Januar 2021 in \u201ePLOS ONE\u201c ver\u00f6ffentlicht wurden. (https:\/\/doi.org\/10.1371\/journal.pone.0244851<\/a>)<\/p>\n\n\n\n

\"\"
Dies ist die erste gesundheits\u00f6konomische Studie zu FlowOxTM, und wir sind \u00fcber die Ergebnisse begeistert.<\/p><\/blockquote>\n\n\n\n

Die kritische Extremit\u00e4tenisch\u00e4mie ist ein schweres Stadium der peripheren Arterienerkrankung der unteren Gliedma\u00dfe, das zu Gewebeverlust, Gangr\u00e4n, Amputation und Tod f\u00fchren kann. Die h\u00e4usliche FlowOx\u2122-Therapie mit ihrem intermittierenden Unterdruck f\u00fchrt zur Steigerung der Durchblutung, Schmerzlinderung und Verbesserung der Wundheilung bei Patienten mit peripherer Arterienerkrankung und kritischer Extremit\u00e4tenisch\u00e4mie.<\/p>\n\n\n\n

Wichtige Schlussfolgerungen:<\/h3>\n\n\n\n

FlowOx\u2122-Therapie-Patienten gewannen 0,27 zus\u00e4tzliche \u201equalit\u00e4tsbereinigte Lebensjahre\u201c (QALY) im Vergleich zu Patienten mit Standardbehandlung. Dies entspricht einem dominanten inkrementellen Kosten-Effektivit\u00e4ts-Verh\u00e4ltnis pro gewonnenem QALY.<\/p>\n\n\n\n

Beim National Institute for Health and Care Excellence-Schwellenwert WTP (Zahlungsbereitschaft) von \u00a320.000 und \u00a330.000 pro gewonnenem QALY hatte die FlowOx\u2122-Therapie zus\u00e4tzlich zur Standardversorgung eine Wahrscheinlichkeit von 0,80 bzw. 1,00, kosteneffektiv zu sein.<\/p>\n\n\n\n

Kosteneffektive Behandlung der peripheren Arterienerkrankung.
Ein FlowOxTM Behandlungszyklus pro Jahr kann eine kosteneffektive Behandlung der peripheren Arterienerkrankung sein. Die FlowOx\u2122-Therapie verbessert hierbei die gesundheitlichen Ergebnisse und reduziert die Behandlungskosten in dieser Kontrollgruppe.<\/p>\n\n\n\n

\"\"
Andreas Mollatt ist CEO von Otivio.<\/em><\/figcaption><\/figure>\n\n\n\n

\u201cDies ist die erste gesundheits\u00f6konomische Studie zu FlowOxTM und wir sind von den Ergebnissen begeistert. Wir sehen dies als wichtigen, erreichten Meilenstein, obwohl wir nat\u00fcrlich weitere klinische und gesundheits\u00f6konomische Evidenz generieren m\u00f6chten“, sagt Andreas Mollat, CEO von Otivio AS.<\/p>\n\n\n\n

<\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Eine neue gesundheits\u00f6konomische Studie der Bangor Universit\u00e4t, Wales, Gro\u00dfbritannien, best\u00e4tigt, dass die FlowOx\u2122-Therapie in Kombination mit der Nominalversorgung die gesundheitsbezogene Lebensqualit\u00e4t der Patienten im Vergleich zur Standardversorgung verbessert und auch f\u00fcr die Kostentr\u00e4ger (in diesem Fall NHS (National Health Service – das staatliche Gesundheitssystem in Gro\u00dfbritannien) kostensparend ist. Die Ergebnisse deuten darauf hin, dass die FlowOx\u2122-Therapie eine wirtschaftlich sinnvolle Behandlung ist.<\/p>\n","protected":false},"author":1,"featured_media":1288,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"boxed-container","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[2],"tags":[6,7],"class_list":["post-1283","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-horizon-2020","tag-improved-quality-of-life"],"featured_image_src":"https:\/\/flowox.com\/de\/wp-content\/uploads\/sites\/10\/2021\/01\/Flowox_happy-scaled-e1611672758494-600x400.jpg","featured_image_src_square":"https:\/\/flowox.com\/de\/wp-content\/uploads\/sites\/10\/2021\/01\/Flowox_happy-scaled-e1611672758494-600x600.jpg","author_info":{"display_name":"flowoxonline","author_link":"https:\/\/flowox.com\/de\/author\/flowoxonline\/"},"uagb_featured_image_src":{"full":["https:\/\/flowox.com\/de\/wp-content\/uploads\/sites\/10\/2021\/01\/Flowox_happy-scaled-e1611672758494.jpg",1179,800,false],"thumbnail":["https:\/\/flowox.com\/de\/wp-content\/uploads\/sites\/10\/2021\/01\/Flowox_happy-scaled-e1611672758494-150x150.jpg",150,150,true],"medium":["https:\/\/flowox.com\/de\/wp-content\/uploads\/sites\/10\/2021\/01\/Flowox_happy-scaled-e1611672758494-300x204.jpg",300,204,true],"medium_large":["https:\/\/flowox.com\/de\/wp-content\/uploads\/sites\/10\/2021\/01\/Flowox_happy-scaled-e1611672758494-768x521.jpg",768,521,true],"large":["https:\/\/flowox.com\/de\/wp-content\/uploads\/sites\/10\/2021\/01\/Flowox_happy-scaled-e1611672758494-1024x695.jpg",1024,695,true],"1536x1536":["https:\/\/flowox.com\/de\/wp-content\/uploads\/sites\/10\/2021\/01\/Flowox_happy-scaled-e1611672758494.jpg",1179,800,false],"2048x2048":["https:\/\/flowox.com\/de\/wp-content\/uploads\/sites\/10\/2021\/01\/Flowox_happy-scaled-e1611672758494.jpg",1179,800,false],"ab-block-post-grid-landscape":["https:\/\/flowox.com\/de\/wp-content\/uploads\/sites\/10\/2021\/01\/Flowox_happy-scaled-e1611672758494-600x400.jpg",600,400,true],"ab-block-post-grid-square":["https:\/\/flowox.com\/de\/wp-content\/uploads\/sites\/10\/2021\/01\/Flowox_happy-scaled-e1611672758494-600x600.jpg",600,600,true],"gb-block-post-grid-landscape":["https:\/\/flowox.com\/de\/wp-content\/uploads\/sites\/10\/2021\/01\/Flowox_happy-scaled-e1611672758494-600x400.jpg",600,400,true],"gb-block-post-grid-square":["https:\/\/flowox.com\/de\/wp-content\/uploads\/sites\/10\/2021\/01\/Flowox_happy-scaled-e1611672758494-600x600.jpg",600,600,true]},"uagb_author_info":{"display_name":"flowoxonline","author_link":"https:\/\/flowox.com\/de\/author\/flowoxonline\/"},"uagb_comment_info":0,"uagb_excerpt":"Eine neue gesundheits\u00f6konomische Studie der Bangor Universit\u00e4t, Wales, Gro\u00dfbritannien, best\u00e4tigt, dass die FlowOx\u2122-Therapie in Kombination mit der Nominalversorgung die gesundheitsbezogene Lebensqualit\u00e4t der Patienten im Vergleich zur Standardversorgung verbessert und auch f\u00fcr die Kostentr\u00e4ger (in diesem Fall NHS (National Health Service - das staatliche Gesundheitssystem in Gro\u00dfbritannien) kostensparend ist. Die Ergebnisse deuten darauf hin, dass die…","_links":{"self":[{"href":"https:\/\/flowox.com\/de\/wp-json\/wp\/v2\/posts\/1283","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flowox.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flowox.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flowox.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flowox.com\/de\/wp-json\/wp\/v2\/comments?post=1283"}],"version-history":[{"count":0,"href":"https:\/\/flowox.com\/de\/wp-json\/wp\/v2\/posts\/1283\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flowox.com\/de\/wp-json\/wp\/v2\/media\/1288"}],"wp:attachment":[{"href":"https:\/\/flowox.com\/de\/wp-json\/wp\/v2\/media?parent=1283"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flowox.com\/de\/wp-json\/wp\/v2\/categories?post=1283"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flowox.com\/de\/wp-json\/wp\/v2\/tags?post=1283"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}